You think investors will come flooding in if they release some scan images to market. Did these investors not believe the clinical data? They need to see and interpret MRI images themselves before investing?
Great to see this trial enrolling 2nd line patients. That, coupled with multiple trial sites, will mean the enrollment rate should be much faster.
Plus we get to see if we get additional benefit at 2nd line.
Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial, page-4
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
